Pharmacotherapy of Child and Adolescent Psychiatric Disorders

王朝导购·作者佚名
 
Pharmacotherapy of Child and Adolescent Psychiatric Disorders  点此进入淘宝搜索页搜索
  特别声明:本站仅为商品信息简介,并不出售商品,您可点击文中链接进入淘宝网搜索页搜索该商品,有任何问题请与具体淘宝商家联系。
  参考价格: 点此进入淘宝搜索页搜索
  分类: 图书,进口原版,Medicine(医学),Pharmacology(药理学),
  品牌: David RosenbergSamuel Gershon

基本信息出版社:Wiley-Blackwell; 3 (2012年2月21日)精装:474页正文语种:英语ISBN:0470973765条形码:9780470973769商品尺寸:17.7 x 2.7 x 24.7 cm商品重量:862 gASIN:0470973765商品描述内容简介This book fulfils an urgent need for an updated text on pediatric psychopharmacology.  It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones.  The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the   differential between active medication and placebo.  It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout.  The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv.  It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression.  Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.Third edition of the first ever book published on pediatric psychopharmacology from renowned editors.Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior.Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD.Features many tables, figures and pictorials, making it highly accessible and reader friendly.作者简介David Rosenberg MD, Miriam L. Hamburger Endowed Chair of Child Psychiatry and Professor & Chief of Child Psychiatry and Psychology at Wayne State University and the Children's Hospital of Michigan, Detroit, MI , USASamuel Gershon MD, Emeritus Professor of Psychiatry, University of Pittsburgh, PA, USA

 
 
免责声明:本文为网络用户发布,其观点仅代表作者个人观点,与本站无关,本站仅提供信息存储服务。文中陈述内容未经本站证实,其真实性、完整性、及时性本站不作任何保证或承诺,请读者仅作参考,并请自行核实相关内容。
© 2005- 王朝网络 版权所有